Repository logo
 
Publication

A case of success: complete response to Radium-223 in metastatic castration-resistant prostate cancer

dc.contributor.authorSoares De Pinho, Inês
dc.contributor.authorEsperança Martins, Miguel
dc.contributor.authorMachado, Bárbara
dc.contributor.authorDâmaso, Sara
dc.contributor.authorBrás, Raquel
dc.contributor.authorCantinho, Guilhermina
dc.contributor.authorFernandes, Isabel
dc.contributor.authorCosta, Luis
dc.date.accessioned2024-11-19T15:38:50Z
dc.date.available2024-11-19T15:38:50Z
dc.date.issued2024
dc.description© Copyright 2024 Soares de Pinho et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are creditedpt_PT
dc.description.abstractRadium-223 dichloride (Ra223) is the first targeted alpha agent approved for treating metastatic castration-resistant prostate cancer (mCRPC) with bone-exclusive disease. A benefit in overall survival and time to the first symptomatic skeletal-related event was shown in the Alpharadin in Symptomatic Prostate Cancer Patients (ALSYMPCA) trial. However, this trial did not describe a bone scan response to Ra223, and there is no universal consensus about how it should be monitored. Furthermore, a scintigraphy flare phenomenon may lead to false-positive tracer uptake in responsive cases, thereby misleading the interpretation of imaging results. We present the case of a 67-year-old male with mCRPC and exclusive bone disease treated with Ra223. The bone scintigraphy after the end of the treatment showed an apparent aggravation of the lesions, corresponding to a flare phenomenon, with an almost complete resolution after three months. The patient maintained a scintigraphic response for seven months.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationCureus. 2024 Feb 5;16(2):e53637pt_PT
dc.identifier.doi10.7759/cureus.53637pt_PT
dc.identifier.eissn2168-8184
dc.identifier.urihttp://hdl.handle.net/10400.5/95443
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherSpringer Naturept_PT
dc.relation.publisherversionhttps://www.cureus.com/pt_PT
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/pt_PT
dc.subjectBone diseasept_PT
dc.subjectFlarept_PT
dc.subjectProstate cancerpt_PT
dc.subjectRadium-223pt_PT
dc.subjectResponsept_PT
dc.titleA case of success: complete response to Radium-223 in metastatic castration-resistant prostate cancerpt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.titleCureuspt_PT
person.familyNameSoares de Pinho
person.familyNameEsperança Martins
person.familyNameLopes Brás
person.familyNameCantinho
person.familyNameCosta
person.givenNameInês
person.givenNameMiguel
person.givenNameRaquel
person.givenNameGuilhermina
person.givenNameLuis
person.identifier1201606
person.identifier.ciencia-id7B10-E6A8-C67E
person.identifier.ciencia-id041E-4ADE-FB64
person.identifier.orcid0000-0002-8377-0179
person.identifier.orcid0000-0002-6858-7341
person.identifier.orcid0000-0001-5150-9235
person.identifier.orcid0000-0002-1096-2241
person.identifier.orcid0000-0002-4782-7318
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublication175aa033-b64e-4a94-b8c8-8bed65034181
relation.isAuthorOfPublicatione73cbe66-c79a-4f6b-9bed-b3af464000db
relation.isAuthorOfPublication305603cb-e914-45ea-a3d0-c4f9ef7bbbe0
relation.isAuthorOfPublicationc727fa0f-151e-43d7-b2a6-6468a5be6cfe
relation.isAuthorOfPublication8a2ab4c6-ba86-4433-b4b7-6256d81890e5
relation.isAuthorOfPublication.latestForDiscoveryc727fa0f-151e-43d7-b2a6-6468a5be6cfe

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
Case_success.pdf
Size:
395.07 KB
Format:
Adobe Portable Document Format
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.2 KB
Format:
Item-specific license agreed upon to submission
Description: